Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 23225792)

1.

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.

Saijo N.

Yonsei Med J. 2013 Jan 1;54(1):1-14. doi: 10.3349/ymj.2013.54.1.1. Review.

2.

Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.

Mack PC, Gandara DR, Lara PN Jr.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1591-6. doi: 10.1586/era.12.135. Review.

PMID:
23253224
3.

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR.

J Clin Oncol. 2010 Nov 1;28(31):4747-54. doi: 10.1200/JCO.2009.27.9356. Epub 2010 Oct 4.

5.

Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.

Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, Tsuji T, Tsujino K, Ou SH, Nakagawa K, Takada M.

J Thorac Oncol. 2011 Nov;6(11):1881-8. doi: 10.1097/JTO.0b013e31822722b6.

PMID:
21841503
6.

Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, Ichinose Y, Katakami N, Yamamoto N, Kudoh S, Sasaki J, Matsui K, Takayama K, Kashii T, Iwamoto Y, Sawa T, Okamoto I, Kurata T, Nakagawa K, Fukuoka M.

J Clin Oncol. 2010 Feb 10;28(5):753-60. doi: 10.1200/JCO.2009.23.3445. Epub 2009 Dec 28.

7.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
9.

"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".

Hann CL, Brahmer JR.

Curr Treat Options Oncol. 2007 Feb;8(1):28-37. Review.

PMID:
17634830
10.

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC.

J Clin Oncol. 2009 Jul 20;27(21):3540-6. doi: 10.1200/JCO.2008.20.8793. Epub 2009 May 26.

11.

Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

Jiang H.

Jpn J Clin Oncol. 2009 Mar;39(3):137-50. doi: 10.1093/jjco/hyn139. Epub 2008 Dec 16. Review.

12.

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).

Akamatsu H, Inoue A, Mitsudomi T, Kobayashi K, Nakagawa K, Mori K, Nukiwa T, Nakanishi Y, Yamamoto N.

Jpn J Clin Oncol. 2013 Jun;43(6):664-8. doi: 10.1093/jjco/hyt049. Epub 2013 Apr 12.

13.

Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.

Kawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K, Furonaka O, Isobe T, Miyoshi S, Hamada H, Yamane T, Yokoyama A, Kohno N.

Respir Res. 2011 Jul 26;12:97. doi: 10.1186/1465-9921-12-97.

14.

The role of gefitinib in the management of Asian patients with non-small cell lung cancer.

Chang AY.

Expert Opin Investig Drugs. 2008 Mar;17(3):401-11. doi: 10.1517/13543784.17.3.401 . Review. Erratum in: Expert Opin Investig Drugs. 2008 May;17(5):825.

PMID:
18321238
15.

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC).

Kobayashi K, Hagiwara K.

Target Oncol. 2013 Mar;8(1):27-33. doi: 10.1007/s11523-013-0258-9. Epub 2013 Jan 30. Review.

16.

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.

Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC.

J Thorac Oncol. 2011 Oct;6(10):1663-9. doi: 10.1097/JTO.0b013e318227816a.

PMID:
21869714
17.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4.

18.

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.

Yang CH.

Lung Cancer. 2008 Jun;60 Suppl 2:S23-30. doi: 10.1016/S0169-5002(08)70102-8. Review.

PMID:
18513581
19.

Gefitinib therapy for non-small cell lung cancer.

Birnbaum A, Ready N.

Curr Treat Options Oncol. 2005 Jan;6(1):75-81. Review.

PMID:
15610717
20.

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, Nishio M.

Anticancer Res. 2013 Aug;33(8):3327-33. Erratum in: Anticancer Res. 2013 Sep;33(9):4137.

PMID:
23898099
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk